Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States

IMPORTANCE: Immune checkpoint inhibitor combination therapy has recently become the standard of care for first-line treatment of metastatic nonsquamous non–small cell lung cancer. The implications of these first-line treatments are considerable, given the potential population of patients eligible to...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Netw Open
Glavni autori: Criss, Steven D., Mooradian, Meghan J., Watson, Tina R., Gainor, Justin F., Reynolds, Kerry L., Kong, Chung Yin
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2019
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6764123/
https://ncbi.nlm.nih.gov/pubmed/31553470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.11952
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items